While Institutions Invested in SOPHiA GENETICS SA (NASDAQ:SOPH) Benefited From Last Week's 17% Gain, Retail Investors Stood to Gain the Most
While Institutions Invested in SOPHiA GENETICS SA (NASDAQ:SOPH) Benefited From Last Week's 17% Gain, Retail Investors Stood to Gain the Most
Key Insights
關鍵見解
Significant control over SOPHiA GENETICS by retail investors implies that the general public has more power to influence management and governance-related decisions
51% of the business is held by the top 10 shareholders
Institutions own 27% of SOPHiA GENETICS
散戶投資者對SopHia GENETICS的嚴格控制意味着公衆擁有更大的影響管理和治理相關決策的權力
51% 的業務由前十名股東持有
機構擁有索菲亞遺傳學27%的股份
To get a sense of who is truly in control of SOPHiA GENETICS SA (NASDAQ:SOPH), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are retail investors with 44% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
要了解誰真正控制了SopHia GENETICS SA(納斯達克股票代碼:SOPH),了解該業務的所有權結構非常重要。而持有最大份額的群體是擁有44%所有權的散戶投資者。換句話說,該集團面臨最大的上行潛力(或下行風險)。
While retail investors were the group that reaped the most benefits after last week's 17% price gain, institutions also received a 27% cut.
儘管散戶投資者是繼上週股價上漲17%之後獲得最大收益的群體,但機構也獲得了27%的下調。
Let's delve deeper into each type of owner of SOPHiA GENETICS, beginning with the chart below.
讓我們從下圖開始,深入研究SopHia GENETICS的每種所有者。
![](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240604/0-870e73465651eeb4ffc375be1a48ed2b-0-18b796f81c4417f0386cfccc91e13c5f.png/big)
NasdaqGS:SOPH Ownership Breakdown June 4th 2024
納斯達克GS:SOPH 所有權明細 2024 年 6 月 4 日
What Does The Institutional Ownership Tell Us About SOPHiA GENETICS?
關於索菲亞遺傳學,機構所有權告訴我們什麼?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
許多機構根據近似於當地市場的指數來衡量自己的表現。因此,他們通常會更多地關注主要指數中包含的公司。
As you can see, institutional investors have a fair amount of stake in SOPHiA GENETICS. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see SOPHiA GENETICS' historic earnings and revenue below, but keep in mind there's always more to the story.
如你所見,機構投資者持有SopHia GENETICS的相當數量的股份。這表明專業投資者有一定的信譽。但是我們不能僅僅依靠這個事實,因爲機構有時會像所有人一樣進行不良投資。當多家機構擁有一隻股票時,總是存在處於 “擁擠交易” 的風險。當這樣的交易出錯時,多方可能會競相快速出售股票。對於沒有增長曆史的公司,這種風險更高。你可以在下面看到SopHia GENETICS的歷史收益和收入,但請記住,故事總是有更多內容。
![](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240604/0-870e73465651eeb4ffc375be1a48ed2b-1-dcff83169d6c347fbe13a35b2ae30fba.png/big)
NasdaqGS:SOPH Earnings and Revenue Growth June 4th 2024
納斯達克GS: SOPH 收益和收入增長 2024 年 6 月 4 日
We note that hedge funds don't have a meaningful investment in SOPHiA GENETICS. Alychlo NV is currently the company's largest shareholder with 11% of shares outstanding. For context, the second largest shareholder holds about 10% of the shares outstanding, followed by an ownership of 7.5% by the third-largest shareholder. In addition, we found that Jurgi Camblong, the CEO has 3.8% of the shares allocated to their name.
我們注意到,對沖基金沒有對索菲亞遺傳學進行有意義的投資。內華達州Alychlo目前是該公司的最大股東,已發行股份爲11%。就背景而言,第二大股東持有約10%的已發行股份,其次是第三大股東持有7.5%的所有權。此外,我們發現首席執行官尤爾吉·坎布隆以其名義分配了3.8%的股份。
On further inspection, we found that more than half the company's shares are owned by the top 10 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.
經進一步檢查,我們發現公司一半以上的股份由前十名股東擁有,這表明較大股東的利益在一定程度上由較小股東所平衡。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
雖然研究公司的機構所有權可以爲你的研究增加價值,但研究分析師的建議以更深入地了解股票的預期表現也是一種很好的做法。有很多分析師報道該股,因此可能也值得一看他們的預測。
Insider Ownership Of SOPHiA GENETICS
索菲亞遺傳學的內部所有權
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
儘管內部人員的確切定義可能是主觀的,但幾乎所有人都認爲董事會成員是內部人士。管理層最終向董事會負責。但是,經理成爲執行董事會成員的情況並不少見,特別是如果他們是創始人或首席執行官。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
當內部所有權表明領導層像公司的真正所有者一樣思考時,內部所有權是積極的。但是,高度的內部所有權也可以賦予公司內部的一小部分人巨大的權力。在某些情況下,這可能是負面的。
We can see that insiders own shares in SOPHiA GENETICS SA. In their own names, insiders own US$19m worth of stock in the US$326m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.
我們可以看到內部人士擁有SopHia GENETICS SA的股份。內部人士以自己的名義擁有這家價值3.26億美元的公司價值1900萬美元的股票。這至少顯示出一定的對齊性。你可以點擊這裏查看這些內部人士是否在買入或賣出。
General Public Ownership
一般公有制
With a 44% ownership, the general public, mostly comprising of individual investors, have some degree of sway over SOPHiA GENETICS. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
擁有44%的所有權的公衆(主要由個人投資者組成)對索菲亞遺傳學有一定程度的影響力。儘管這種所有權規模可能不足以影響對他們有利的政策決定,但它們仍然可以對公司政策產生集體影響。
Private Equity Ownership
私募股權所有權
With a stake of 23%, private equity firms could influence the SOPHiA GENETICS board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.
私募股權公司持有23%的股份,可能會影響索菲亞遺傳學董事會。一些投資者可能會爲此感到鼓舞,因爲私募股權有時能夠鼓勵制定有助於市場看到公司價值的策略。或者,這些持有人可能會在投資上市後退出投資。
Next Steps:
後續步驟:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for SOPHiA GENETICS that you should be aware of.
我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,我們已經確定了你應該注意的索菲亞遺傳學的一個警告信號。
If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.
如果你想了解分析師對未來增長的預測,千萬不要錯過這份關於分析師預測的免費報告。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。